NCBiotech News

Areteia Therapeutics Inc., a clinical-stage biotechnology company based in Chapel Hill, has reported positive results from the Phase III EXHALE-4 efficacy and safety study of the investigational drug dexpramipexole as an add-on oral therapy for eosinophilic asthma.

The U.S. military has the most advanced technology of any fighting force, but there’s still room for improvement when it comes to medical equipment, supplies and devices used in combat.

That assessment came from speakers at the Medical, Biomedical and Biodefense Symposium held in late September at the Friday Center at UNC-Chapel Hill.

Burlington-based Labcorp has launched the first blood-based test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the diagnosis of Alzheimer's disease. 

Available nationwide, the Lumipulse® pTau-217/Beta Amyloid 42 Ratio blood test is designed to detect amyloid plaques associated with the disease in adult patients 50 and older with signs and symptoms of the disease. 

Wake Technical Community College is developing a new campus in Apex that will play a key role in preparing students for careers in biotechnology and health sciences in western Wake County. The Wake Tech Board of Trustees recently approved the master plan for the new Conlon Western Wake Campus, which is projected to open in 2029.

If you want to know how therapeutic innovation in the Triangle stacks up against other life sciences hubs, just ask an investor who knows the national and global landscape.

Nima Ronaghi, principal at Breakout Ventures, a San Francisco fund that invests in early-stage, science-backed companies, said the Triangle’s maturity as a life sciences hub was evident at a recent Triangle Venture Day event.

Rubbing elbows in a unique Raleigh corporate incubator are founders of a firm with AI-powered genetic technology for hire, a startup that’s engineering plants to fight cattle burping, and a developer of natural, biodegradable pellets and seed coatings to improve application of agricultural pesticides and nutrients.

N.C. Gov. Josh Stein joined FUJIFILM Biotechnologies leaders and local officials at a ribbon-cutting ceremony for the company’s new $3.2 billion biomanufacturing site in Holly Springs on Wednesday.

Durham Technical Community College and Novo Nordisk officials broke ground this week on a new $41.2 million life sciences education center that will prepare students for careers in North Carolina's booming biotechnology sector.

Believer Meats, a Chicago-based company commercializing cultivated meat made from animal cells, has completed construction of Phase 1 of its 200,000-square-foot manufacturing facility in Wilson, N.C., and aims to be operational by the end of the year. 

Winston-Salem startup BMI OrganBank has received a Breakthrough Device designation from the FDA for its kidney preservation device, which aims to significantly increase the utilization of donated kidneys.

FUJIFILM Biotechnologies, a global contract development and manufacturing organization (CDMO) for biologics, vaccines and advanced therapies, has another drug lined up for its new production plant in Holly Springs.

Life sciences titan Thermo Fisher Scientific, employing 7,800 people at 13 sites across North Carolina, has opened a new manufacturing facility in Mebane that will add nearly 100 more jobs.

The 375,000-square-foot site will be capable of producing at least 40 million laboratory pipette tips per week to support growing demand by the scientific and medical research industries.

Wilmington-based Predicate AI Labs Inc. has entered a collaboration with the Mayo Clinic to advance the early detection of sepsis, the leading cause of mortality worldwide. The healthcare technology company is developing a predictive artificial intelligence platform that can quickly identify critical illness, with an initial focus on sepsis. 

RTP-based Incyclix Bio LLC has secured a $11.25 million extension to its Series B financing. 

The additional funding will help Incyclix Bio advance its first-in-human clinical trial of INX-315, an oral inhibitor of cyclin-dependent kinase 2 (CDK2) being developed to treat advanced and resistant cancer.

Two of the world’s largest life sciences companies have expanded their previously announced partnership to produce advanced medicines in North Carolina.